'김갑성' 기자의 전체기사
-
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated Study is expected to
- 김갑성 기자
- 2026-02-27 04:34
-
ArisGlobal Launches NavaX Translation to Eliminate Manua…
Strategic partnership with TransPerfect Life Sciences embeds certified, pharma-grade translation directly into LifeSphere Safety workflows BOSTON, Feb. 26, 2026 -- ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, recently announced the launch of NavaX Translation, a new solution delivered through a strategic partnership with TransPerfect Life Sciences. NavaX Translation brings certified, pharma-grade translation and multilingual content directly into LifeSphere Safety workflows, enabling faster, more accurate, and full
- 김갑성 기자
- 2026-02-26 22:12
-
Davenport Aviation Successfully Completes Virtus "First Shot," V…
COLUMBUS, Ohio, Feb. 26, 2026 -- Davenport Aviation announced the successful completion of Virtus First Shot testing last month in west Texas, marking a major milestone in the development of the Virtus modular weapon system and the first weaponized test of the Virtus H125 platform. The campaign included multiple successful rocket launches, officially validating Virtus as a proven, weaponized AS350/H125 configuration. The successful firing confirmed the structural integrity, system integration, and operational viability of Virtus on the AS350/H125 airframe. With these results, D
- 김갑성 기자
- 2026-02-26 21:45
-
Davenport Aviation、AS350/H125の武器化を検証するVirtus実弾射撃試験に初成…
オハイオ州コロンバス, 米国, 2026年2月26日 -- Davenport Aviationは、先月テキサス州西部でVirtus初となる実弾射撃試験、いわゆる「First Shot」に成功した旨を発表しました。これはVirtusモジュール兵器システムの開発における飛躍的進歩の証であり、Virtus H125プラットフォーム初の兵器化試験となるものです。Virtusは今回の試験で複数のロケット打ち上げに成功したことにより、AS350/H125武器化の実証済み構成として正式に認定されました。 発射の成功により、AS350/H125機体におけるVirtusの構造的完全性、システム統合、運用可能性が確認されました。これらの結果を出したことで、Davenport Aviationは現代の軍事・安全保障活動を支援可能な、完全に機能的かつ任務遂行可能な武装構成を実証したことになります。 Davenport Aviationの航空機・航空機システム担当副社長を務めるRob McMillin氏は、「これはDavenport AviationとVirtusにとって重要な節目となるものです。今回、実弾射撃試験で初成功を収めたことで、システムを支える技術が検証され、H125が兵器化構成でも安全かつ効果的に運用できることが証明されました」と語りました。&nb
- 김갑성 기자
- 2026-02-26 21:45
-
대븐포트 에이비에이션, 비르투스 '1차 발사' 성공적으로 완료… 무장형 AS350/H125 플랫…
콜럼버스, 오하이오, 2026년 2월 26일 -- 대븐포트 에이비에이션(Davenport Aviation)이 지난달 미국 텍사스주 서부에서 비르투스(Virtus) '1 차 발사(First Shot)' 시험을 성공적으로 완료했다고 발표했다. 이는 비르투스 모듈식 무장 시스템 개발의 주요 이정표이자 비르투스 H125 플랫폼의 첫 무장 시험이다. 이번 시험 캠페인에서는 다수 로켓이 성공적으로 발사됐으며, 이를 통해 비르투스가 검증된 무장형 AS350/H125 구성임이 공식 확인됐다. 이번 발사 성공으로 AS350/H125 기체에서 비르투스의 구조적 무결성, 시스템 통합성, 운용 적합성이 입증됐다. 대븐포트 에이비에이션은 이번 결과를 통해 현대 군사 및 안보 작전을 지원할 수 있는 완전한 기능의 임무 준비형 무장 구성(Mission-Ready Armed Configuration)을 실증했다. 롭 맥밀린(Rob McMillin) 대븐포트 에이비에이션 항공기 및 항공기 시스템 부문 부사장은 "이번 시험은 대븐포트 에이비에이션과 비르투스 팀에 있어 중대한 이정표"라며 "1차 발사 시험 캠페인을 성공적으로
- 김갑성 기자
- 2026-02-26 21:45
-
SK bioscience, IDT Biologika and Vaxxas Selected for Next-G…
SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines in Europe to improve vaccine performance and access. Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats. INCHEON, South Korea, Feb. 26, 2026 -- SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been selected for Phase 1 of a next-generation vaccine development initiative managed by the European Health and Digital Executive Agency (HaDEA) on beha
- 김갑성 기자
- 2026-02-26 21:00
-
CJ BIO Publishes Clinical Study on BiomeNrich™ POST SZ075, a Po…
SEOUL, South Korea, Feb. 26, 2026 -- CJ BIO announced the publication of clinical research findings on its postbiotic ingredient, BiomeNrich™ POST SZ075, in an international peer-reviewed journal. The study strengthens the scientific foundation of the ingredient and supports its positioning as a science-based inner beauty solution. Growing Importance of Scientific Validation in the Inner Beauty Market The global beauty and personal care market is rapidly shifting toward "Beauty from within" approaches that improve skin condition through internal health
- 김갑성 기자
- 2026-02-26 18:40
-
HealthTech Partners Global Expands Clinical Education Divis…
RICHMOND, Va., Feb. 26, 2026 -- HealthTech Partners Global today announced a major expansion of its international clinical education division, alongside the appointment of strategic advisor Rusty Page, whose expertise in operations, quality, and IT will strengthen the company's global infrastructure. Under the leadership of former DIH Commercial Vice President of North America & Asia Pacific, Allison Krumpe, the organization is evolving from a commercial consulting and service-focused model into a comprehensive rehabilitation solutions provider, providing end-to-end support across
- 김갑성 기자
- 2026-02-26 18:05
-
Health Awareness Week Underscores the Importance of Res…
NEW YORK, Feb. 26, 2026 -- As Health Awareness Week brings focus to preventive care and chronic condition management, VARON is highlighting the vital role respiratory health plays in overall well-being. Through its "Your Health, Our Commitment" initiative, the company is promoting greater awareness of breathing health while expanding access to supportive solutions for individuals managing long-term respiratory needs. While cardiovascular health and metabolic conditions often dominate public discussion, respiratory health remains a foundational—yet freque
- 김갑성 기자
- 2026-02-26 16:42
-
genOway: Revolutionizing the Prediction of Antibody Therap…
LYON, France, Feb. 26, 2026 -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety. Why Antibody Therapies Fail in Late-Stage Testing Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflamm
- 김갑성 기자
- 2026-02-26 16:15
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-02-27_FRI
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial 04:34
- Huawei Debuts Cutting-Edge Innovations in Madrid with Focus on Running Watches 01:08
- HCLTech to drive dialogues on AI-native future of telecom industry at MWC 2026 00:52
2026-02-26_THU
- J Law Sets Two-Year Record With 1,499% Return in U.S. Investing Championship 22:31
- ArisGlobal Launches NavaX Translation to Eliminate Manual Translation in Global Pharmacovigilance 22:12
- NYSE Content Update: 'Patty' at Center of Burger King's New BK Assistant AI Solution 22:10
- Davenport Aviation Successfully Completes Virtus "First Shot," Validating Weaponized AS350/H125 Platform 21:45
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 02월 27일 06시 00분